Record mula sa primary source
MateryalTinanggap ang aplikasyon
Boundless Bio: Tinanggap ng FDA ang IND para sa BBI-940 Kinesin degrader
Tinanggap ng FDA ang IND para sa BBI-940 noong Enero 2026, na nagbibigay-daan sa pagbubukas ng KOMODO-1 first-in-human trial para sa pagpapatala sa ER+/HER2- at TNBC-LAR breast cancer. Mayroon na ngayong aktibong klinikal na programa ang kumpanya na may cash runway hanggang H2 2028 na sumasakop sa inaasahang paunang proof-of-concept readout.
Mahahalagang fact
- Na-file
- Mar 9, 2026, 11:05 AM
- Kaganapan
- Tinanggap ang aplikasyon
- Direksyon
- Positibo
- Kumpanya
BOLDBoundless Bio, Inc.- Asset
- BBI-940
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
EX-99.1 2 bold-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 – Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2025. "With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited